"Mpox Vaccination: Efficacy, Breakthrough Cases, and Future Directions for 2024"
A s the global health landscape evolves, understanding the effectiveness of Mpox (Mpox Virus, MPXV) vaccinations is crucial. This blog delves into the current state of Mpox vaccination, including recent efficacy studies, breakthrough cases, and future considerations. Whether you're a healthcare professional, researcher, or simply interested in public health, this comprehensive overview will provide valuable insights. Current State of Mpox Vaccination Efficacy of MVA–BN Vaccine Recent studies have highlighted the effectiveness of the MVA–BN smallpox vaccine in preventing symptomatic Mpox infection. A study in England demonstrated that a single dose of the MVA–BN vaccine offered an impressive 78% protection against symptomatic infection from 14 days post-vaccination. However, protection was negligible within the first 13 days. Postexposure Prophylaxis (PEP) Studies France: A study involving 276 individuals who received the MVA–BN vaccine as PEP within 11 days of high-risk ...